September 19, 2022
1 min read
Source/Disclosures
Published by:
Arepalli S, et al. The heterogeneous presentations of de-novo and recurrent uveitis following COVID-19 vaccination – A multi-center report. Presented at: Women in Ophthalmology Summer Symposium; Aug. 25-28, 2022; Monterey, California (hybrid meeting).
Disclosures:
Arepalli reports no relevant financial disclosures.
MONTEREY, Calif. — A study carried out across seven centers in the U.S. found that ocular inflammation might occur in a minority of subjects after COVID-19 vaccination.
“The utility of the COVID-19 vaccination is indisputable; however, rarely, inflammation has been at least temporally associated with the COVID-19 vaccination,” Sruthi Arepalli, MD, and co-authors wrote in a poster presented at the Women in Ophthalmology Summer Symposium.
A retrospective chart review was conducted in a cohort of 321 subjects. Inflammation following COVID-19 vaccination occurred in 37 subjects; 22 (6.8%) had no history of ocular inflammation, and 15 (4.6%) had a history of inflammation that was quiescent for at least 3 months. The vaccines used were Pfizer and Moderna in the majority of cases.
Flares included anterior, intermediate, posterior and panuveitis, as well as scleritis, optic nerve edema, retinal vasculitis, cystoid macular edema, optic neuritis and peripheral ulcerative keratitis. Five subjects in both the de novo and recurrent inflammation groups were HLA-B27 positive.
Flares occurred between 1 and 39 days from vaccination. Quiescence was obtained in most eyes, mainly with topical and oral corticosteroids.












